Ингибиторозащищённые бета-лактамы на основе диазобициклооктанов: механизмы устойчивости грамотрицательных бактерий

Внедрение в медицинскую практику ингибиторозащищённых бета-лактамов на основе диазобициклооктанов существенным образом расширило возможности лечения инфекций, вызванных грамотрицательными бактериями, продуцирующими карбапенемазы. Однако реальный прогресс в лечении инфекций оказался меньше ожидаемого из-за быстрого формирования и распространения резистентности к новым препаратам. В обзоре суммированы и проанализированы современные данные о механизмах устойчивости к ингибиторозащищённым бета-лактамам.

1. WHO.: WHO bacterial priority pathogens list, 2024: bacterial pathogens of public health importance, to guide research, development and strategies to prevent and control antimicrobial resistance. Geneva: World Health Organization. 2024.

2. Ma J, Song X, Li M, Yu Z, Cheng W, Yu Z, Zhang W, Zhang Y, Shen A, Sun H, et al. Global spread of carbapenem-resistant Enterobacteriaceae: Epidemiological features, resistance mechanisms, detection and therapy. Microbiol Res. 2023, 266: 127249. doi: 10.1016/j.micres.2022.127249.

3. Murray CJL, Ikuta KS, Sharara F, Swetschinski L, Robles Aguilar G, Gray A, Han C, Bisignano C, Rao P, Wool E, et al. Global burden of bacterial antimicrobial resistance in 2019: a systematic analysis. Lancet 2022. 399 (10325): 629–655. doi: 10.1016/S0140-6736(21)02724-0.

4. Яковлев С.В., Суворова М.П., Белобородов В.Б., Басин Е.Е., Елисеева Е.В., Ковеленов С.В., Портнягина У.С., Рог А.А., Руднов В.А., Барканова О.Н. Распространённость и клиническое значение нозокомиальных инфекций в лечебных учреждениях России: исследование ЭРГИНИ. Антибиотики и химиотер. 2016; 61 (5–6): 32–42.

5. Wang C, Bai C, Chen K, Du Q, Cheng S, Zeng X, Wang Y, Dong Y. International guidelines for the treatment of carbapenem-resistant Gram-negative bacilli infections: a comparison and evaluation. Int J Antimicrob Agents. 2024; 63 (5): 107120.

6. Tamma PD, Heil EL, Justo JA, Mathers AJ, Satlin MJ, Bonomo RA: Infectious Diseases Society of America 2024 Guidance on the Treatment of Antimicrobial-Resistant Gram-Negative Infections. Clinical Infectious Diseases 2024. doi: 10.1016/j.ijantimicag.2024.107120.

7. Белобородов В.Б., Голощапов О.В., Гусаров В.Г., Дехнич А.В., Замятин М.Н., Золотухин К.Н., Зубарева Н.А., Зырянов С.К., Камышова Д.А., Климко Н.Н. и др. Диагностика и антимикробная терапия инфекций, вызванных полирезистентными микроорганизмами» (обновление 2024 года). Вестник анестезиологии и реаниматологии. 2025; 22 (2): 149–189.

8. Bonomo RA, Perez F, Hujer AM, Hujer KM, Vila AJ. The real crisis in antimicrobial resistance: failure to anticipate and respond. Clin Infect Dis. 2024; 78 (6): 1429–1433. doi: 10.1093/cid/ciad758.

9. Егоров А.М., Уляшова М.М., Рубцова М.Ю. Ингибиторы β-лактамаз. Новая жизнь β-лактамных антибиотиков. Биохимия. 2020; 85 (11): 1519–1539.

10. Bush K, Bradford PA. Interplay between β-lactamases and new β-lactamase inhibitors. Nature Reviews Microbiology. 2019; 17 (5): 295–306. doi: 10.1038/s41579-019-0159-8.

11. Kaye KS, Belley A, Barth P, Lahlou O, Knechtle P, Motta P, Velicitat P. Effect of cefepime/enmetazobactam vs piperacillin/tazobactam on clinical cure and microbiological eradication in patients with complicated urinary tract infection or acute pyelonephritis: a randomized clinical trial. Jama. 2022; 328 (13): 1304–1314. doi: 10.1001/jama.2022.17034.

12. Coleman K. Diazabicyclooctanes (DBOs): a potent new class of nonbeta-lactam beta-lactamase inhibitors. Curr Opin Microbiol. 2011; 14 (5): 550–555. doi: 10.1016/j.mib.2011.07.026.

13. Bonnefoy A, Dupuis-Hamelin C, Steier V, Delachaume C, Seys C, Stachyra T, Fairley M, Guitton M, Lampilas M. In vitro activity of AVE1330A, an innovative broad-spectrum non-beta-lactam beta-lactamase inhibitor. J Antimicrob Chemother. 2004; 54 (2): 410–417. doi: 10.1093/jac/dkh358.

14. Ehmann DE, Jahic H, Ross PL, Gu RF, Hu J, Durand-Reville TF, Lahiri S, Thresher J, Livchak S, Gao N et al. Kinetics of avibactam inhibition against class A, C, and D beta-lactamases. J Biol Chem. 2013; 288 (39): 27960–27971. doi: 10.1074/jbc.M113.485979.

15. Nägeli M, Rodriguez S, Iradukunda A, Manson AL, Earl AM, BrennanKrohn T. Rapid emergence of resistance to broad-spectrum direct antimicrobial activity of avibactam. Microbiol Spectr. 2025; 13 (8): e0324124. doi: 10.1128/spectrum.03241-24.

16. Sutaria DS, Moya B, Green KB, Kim TH, Tao X, Jiao Y, Louie A, Drusano GL, Bulitta JB. First Penicillin-binding protein occupancy patterns of β-lactams and β-lactamase inhibitors in Klebsiella pneumoniae. Antimicrob Agents Chemother. 2018; 62 (6): e00282-18. doi: 10.1128/AAC.00282-18.

17. Wagenlehner FM, McGovern PC, Moeck G. Cefepime–taniborbactam in complicated urinary tract infection. Reply. N Engl J Med. 2024; 390 (20): 1938–1939. doi: 10.1056/NEJMc2403590.

18. Sheu CC, Chang YT, Lin SY, Chen YH, Hsueh PR. Infections caused by carbapenem-resistant enterobacteriaceae: an update on therapeutic options. Front Microbiol. 2019; 10: 80. doi: 10.3389/fmicb.2019.00080.

19. Компания Pfizer зарегистрировала в России препарат Завицефта (цефтазидим–авибактам). Антибиотики и химиотерапия. 2017.

20. Bhatnagar A, Ransom EM, Machado MJ, Boyd S, Reese N, Anderson K, Lonsway D, Elkins CA, Rasheed JK, Patel JB, et al. Assessing the in vitro impact of ceftazidime on aztreonam/avibactam susceptibility testing for highly resistant MBL-producing Enterobacterales. J Antimicrob Chemother. 2021; 76 (4): 979–983. doi: 10.1093/jac/dkaa531.

21. Heo YA. Imipenem/cilastatin/relebactam: a review in gram-negative bacterial infections. Drugs.2021; 81 (3): 377–388. doi: 10.1007/s40265-021-01471-8.

22. McLeod SM, O'Donnell JP, Narayanan N, Mills JP, Kaye KS. Sulbactamdurlobactam: a β-lactam/β-lactamase inhibitor combination targeting Acinetobacter baumannii. Future Microbiol. 2024; 19 (7): 563–576. doi: 10.2217/fmb-2023-0248.

23. Shapiro AB, Moussa SH, McLeod SM, Durand-Réville T, Miller AA. Durlobactam, a new diazabicyclooctane β-lactamase inhibitor for the treatment of acinetobacter infections in combination with sulbactam. Front Microbiol. 2021; 12: 709974. doi: 10.3389/fmicb.2021.709974.

24. Boattini M, Gaibani P, Comini S, Costa C, Cavallo R, Broccolo F, Bianco G. In vitro activity and resistance mechanisms of novel antimicrobial agents against metallo-β-lactamase producers. Eur J Clin Microbiol Infect Dis. 2025; 44 (5): 1041–1068. doi: 10.1007/s10096-025-05080-1.

25. Le Terrier C, Nordmann P, Delaval A, Poirel L. Potent in vitro activity of sulbactam-durlobactam against NDM-producing Escherichia coli including cefiderocol and aztreonam-avibactam-resistant isolates. Clin Microbiol Infect. 2025; 31 (1): 122–124. doi: 10.1016/j.cmi.2024.10.012.

26. Fouad A, Nicolau DP, Gill CM. In vitro synergy of the combination of sulbactam-durlobactam and cefepime at clinically relevant concentrations against A. baumannii, P. aeruginosa and Enterobacterales. J Antimicrob Chemother. 2023; 78 (12): 2801–2809. doi: 10.1093/jac/dkad244.

27. Wang Y, Wang J, Wang R, Cai Y. Resistance to ceftazidime–avibactam and underlying mechanisms. J Glob Antimicrob Resist. 2020; 22: 18–27. doi: 10.1016/j.jgar.2019.12.009.

28. Mushtaq S, Vickers A, Ellaby N, Woodford N, Livermore DM. Selection and characterization of mutational resistance to aztreonam/avibactam in β-lactamase-producing Enterobacterales. J Antimicrob Chemother. 2021; 77 (1): 98–111. doi: 10.1093/jac/dkab346.

29. Abichabki N, Gaspar GG, Bortolato LR, Lima DAFS, Silva LN, Pocente RHC, Ferreira JC, Ogasawara TC, Pereira D, Guerra RR, et al. Ceftazidime-avibactam tolerance and persistence among difficult-to-treat KPC-producing Klebsiella pneumoniae clinical isolates from bloodstream infections. Eur J Clin Microbiol Infect Dis. 2025; 44 (2): 343–353. doi: 10.1007/s10096-024-05005-4.

30. Livermore DM, Mushtaq S, Vickers A, Woodford N. Activity of aztreonam/avibactam against metallo-β-lactamase-producing Enterobacterales from the UK: Impact of penicillin-binding protein-3 inserts and CMY-42 β-lactamase in Escherichia coli. Int j Antimicrob Agents. 2023; 61 (5): 106776. doi: 10.1016/j.ijantimicag.2023.106776.

31. Sadek M, Juhas M, Poirel L, Nordmann P. Genetic features leading to reduced susceptibility to aztreonam–avibactam among metallo-β-lactamase-producing Escherichia coli isolates. Antimicrob Agents Chemother. 2020; 64 (12): e01659–20. doi: 10.1128/AAC.01659-20.

32. Sethuvel DPM, Bakthavatchalam YD, Karthik M, Irulappan M, ShrivastavaR, Periasamy H, Veeraraghavan B. β-Lactam resistance in ESKAPE pathogens mediated through modifications in penicillin-binding proteins: an overview. Infect Dis Ther. 2023; 12 (3): 829–841. doi: 10.1007/s40121-023-00771-8.

33. Ranjitkar S, Reck F, Ke X, Zhu Q, McEnroe G, Lopez SL, Dean CR. Identification of mutations in the mrda gene encoding PBP2 that reduce carbapenem and diazabicyclooctane susceptibility of escherichia coli clinical isolates with mutations in ftsI (PBP3) and which carry blaNDM-1. mSphere. 2019; 4 (4): e00074–19. doi: 10.1128/mSphere.00074-19.

34. Sadek M, Juhas M, Poirel L, Nordmann P. Genetic features leading to reduced susceptibility to aztreonam-avibactam among metallo-β-lactamase-producing Escherichia coli isolates. Antimicrob Agents Chemother. 2020; 64 (12): e01659–20. doi: 10.1128/AAC.01659-20.

35. Mushtaq S, Vickers A, Woodford N, Livermore DM. Activity of aztreonam/avibactam and ceftazidime/avibactam against Enterobacterales with carbapenemase-independent carbapenem resistance. Int J Antimicrob Agents. 2024; 63 (3): 107081. doi: 10.1016/j.ijantimicag.2023.107081.

36. Chulkova P, Ageevets V, Sulian O, Avdeeva A, Shapovalova V, Matsvay A, Nurmukanova V, Shipulin H, Chernenkaya N, Sidorenko S. Emergence of Escherichia coli harboring mosaic (hypervirulent and multidrugresistant) plasmids that may have been acquired from Klebsiella pneumoniae. 33th European Congress of Clinical Microbiology & Infectious Diseases. Denmark, Copenhagen. 15–18 April 2023. Abstract book.

37. Ma K, Zong Z. Resistance to aztreonam-avibactam due to CTX-M-15 in the presence of penicillin-binding protein 3 with extra amino acids in Escherichia coli. Front Microbiol. 2022; 13: 1047109. doi: 10.3389/fmicb.2022.1047109.

38. Xu M, Fu Y, Zhang Y, Kong H, Zhao W, Zeng H. Emergence of transferable aztreonam-avibactam resistance in the high-risk ST44 subclade of carbapenemase-producing Providencia hangzhouensis, 2012–2023. J Infect. 2025; 91 (2): 106562. doi: 10.1016/j.jinf.2025.106562.

39. Zhang B, Zhu Z, Jia W, Qu F, Huang B, Shan B, Yu H, Tang Y, Chen L, Du H. In vitro activity of aztreonam–avibactam against metallo-β-lactamaseproducing Enterobacteriaceae — a multicenter study in China. Int J Infect Dis. 2020; 97: 11–18. doi: 10.1016/j.ijid.2020.05.075.

40. Karlowsky JA, Hackel MA, McLeod SM, Miller AA. In vitro activity of sulbactam-durlobactam against global isolates of Acinetobacter baumannii calcoaceticus complex collected from 2016 to 2021. Antimicrob Agents Chemother. 2022; 66 (9): e00781–00722. doi: 10.1128/aac.00781-22.

41. Principe L, Di Bella S, Conti J, Perilli M, Piccirilli A, Mussini C, Decorti G. Acinetobacter baumannii resistance to sulbactam/durlobactam: a systematic review. Antibiotics. 2022; 11 (12): 1793. doi: 10.3390/antibiotics11121793.

42. Buyukyanbolu E, Argotsinger J, Beck ET, Chamberland RR, Clark AE, Daniels AR, Liesman R, Fisher M, Gialanella P, Hand J, et al. Activity of ampicillin-sulbactam, sulbactam-durlobactam, and comparators against Acinetobacter baumannii-calcoaceticus complex strains isolated from respiratory and bloodstream sources: results from ACNBio study. Antimicrob Agents Chemother. 2025; 69 (8): e0037925. doi: 10.1128/aac.00379-25.

43. Pogue JM, Harrington J, Wangchinda W, Kaye KS. New perspectives on antimicrobial agents: sulbactam-durlobactam. Antimicrobial Agents Chemother. 2025; 69 (10): e0108624. doi: 10.1128/aac.01086-24.